Project Description

Scaling Health Interventions for Effective Long-term Dengue Control (SHIELD): Implementation and policy research for scaling up Wolbachia in Indonesia

Summary

SHIELD addresses the challenges of scaling and integrating Wolbachia replacement technology, a proven method for controlling dengue and other arboviral diseases, into national dengue control programmes. With Indonesia facing one of the highest dengue burdens in the world, the programme aims to increase the reach and impact of Wolbachia-based dengue control in Indonesia and to generate insights for broader global adoption.

01 / GLOBAL EXPOSURE
4 billion+

people threatened by dengue worldwide

02 / ECONOMIC BURDEN
US$9 bn

estimated global cost of dengue each year

03 / GLOBAL CASES
14.4 m

dengue cases and 11,000 deaths reported globally in 2024, a record

04 / INDONESIA
257,000

hospitalised dengue cases and 1,461 deaths in Indonesia, 2024

The challenge

Conventional measures such as insecticide fogging have failed to curb surging dengue transmission, which is driven by urbanisation, climate change and global mobility. New tools, including Wolbachia and Takeda’s QDENGA® vaccine, offer new hope, and there is an urgent need to accelerate their uptake into disease control programmes.

Wolbachia

Wolbachia is a naturally occurring bacterium. When introduced into Aedes aegypti mosquitoes, it reduces their ability to transmit dengue and other arboviruses. Trials by our team, including the pivotal efficacy study in Yogyakarta, showed significant and sustained reductions in dengue incidence after Wolbachia releases.

  1. 2017–2020

    Pivotal efficacy trial in Yogyakarta

  2. 2021–2025

    National Dengue Control Strategy names Wolbachia a key innovation

  3. 2022–2025

    Ministry of Health pilots programmatic delivery in five cities

  4. SHIELD

    Lessons from the 5 Cities Project for national and global scale-up

OVERARCHING GOAL

To derive lessons from Indonesia’s 5 Cities Project, a pilot Wolbachia implementation initiative, to inform strategies for national and global scale-up.

SHIELD builds on our team’s decade-long translational research collaboration to bridge the evidence-to-action gap and maximise the reach and impact of new tools against epidemic arboviral disease.

Specific objectives

01

Evaluate Deployment Feasibility

Evaluate the feasibility, acceptability and effectiveness of Wolbachia deployment under programmatic conditions.

02

Identify Scaling Adaptations

Identify critical intervention components and the adaptations required to maintain effectiveness during scaling.

03

Assess Long-Term Outcomes

Address knowledge gaps on long-term entomological and epidemiological outcomes.

04

Co-design Operational Models

Engage stakeholders in co-design of sustainable and scalable operational models.

05

Inform Integrated Dengue Control

Inform strategic decisions on integrating Wolbachia and vaccination into dengue control in Indonesia.

06

Support Global Policy and Practice

Leverage Indonesia’s experience to inform global policy and practice for arboviral disease control.

Four interrelated work packages (WP)

WP 1

Implementation research

Systematic assessment of resources, capabilities, barriers and enablers for effective scale-up of Wolbachia.

WP 2

Entomological studies

Operational and ecological factors affecting Wolbachia establishment, and the field resilience of the intervention to heatwave conditions.

WP 3

Public health impact

Dengue case reductions from routine surveillance and prospective clinic-based studies, with seroprevalence surveys to guide Wolbachia and vaccine targeting.

WP 4

Economic and disease modelling

Cost-benefit and budget impact of Wolbachia under programmatic conditions, and optimal integration with dengue vaccination campaigns.

Expected impact

01

In Indonesia

A feasible and effective model for scaling up Wolbachia, contributing to the national goal of building innovations into evidence-based policy and practice, and supporting nationwide scale-up to reduce dengue illness and deaths.

02

Globally

Critical evidence for decision-making and operational planning on integrated arboviral disease control, including cost-effective and equitable targeting of Wolbachia and vaccination programmes.


Funding


Collaborators


Duration

4 Years


Principal Investigator

Citra Indriani


​